Biogen expects $164 million Q2 2026 charge, a $0.95 per share hit to earnings
Biogen said its second-quarter 2026 GAAP and non-GAAP results will include about $164 million in pre-tax acquired in-process R&D, upfront and milestone expense, reducing diluted earnings per share by about $0.95. It also expects third-quarter charges of $290 million to $320 million, or $1.75 to $1.95 per diluted share, tied to potential milestones and transactions that have not yet closed. Shareholders face lower reported earnings in both quarters, and the second-quarter figures are preliminary.
Key points
- Q2 2026 acquired IPR&D, upfront and milestone expense: about $164 million pre-tax, about $0.95 per diluted share
- Q3 2026 expected expense: $290 million to $320 million, about $1.75 to $1.95 per diluted share
- Q3 estimate relates to potential milestones and transactions that have not yet closed
- Quarter ended June 30, 2026 results have not been finalized and may differ from these estimates
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.